Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Respirics Inc.
DescriptionNew formulation of a short-acting inhaled beta 2-adrenergic agonist
Molecular Target Adrenergic receptor beta 2 (ADRB2)
Mechanism of ActionAdrenergic receptor beta 2 (ADRB2) agonist
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationAsthma
Indication DetailsTreat asthma
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today